Thanks Mozz. I agree a larger trial would be needed - and my thinking that if this is the case, it'd be a shame to not utilise the upcoming trials with thousands of patients to gather that data (and also potentially have DMOAD at the start of regulatory approval rather than after a few years of sales).
And thanks Dungiven, but wasn't really the same question.
Ann: Investor Presentation - $66m Capital Raise, page-10
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 543 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 544 | 1 |
View Market Depth
| Last trade - 09.07am 01/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
Day chart unavailable